Cani Patrice D, de Vos Willem M
Walloon Excellence in Life Sciences and Biotechnology (WELBIO), Metabolism and Nutrition Research Group, Louvain Drug Research Institute, Université catholique de LouvainBrussels, Belgium.
Laboratory of Microbiology, Wageningen UniversityWageningen, Netherlands.
Front Microbiol. 2017 Sep 22;8:1765. doi: 10.3389/fmicb.2017.01765. eCollection 2017.
Metabolic disorders associated with obesity and cardiometabolic disorders are worldwide epidemic. Among the different environmental factors, the gut microbiota is now considered as a key player interfering with energy metabolism and host susceptibility to several non-communicable diseases. Among the next-generation beneficial microbes that have been identified, is a promising candidate. Indeed, is inversely associated with obesity, diabetes, cardiometabolic diseases and low-grade inflammation. Besides the numerous correlations observed, a large body of evidence has demonstrated the causal beneficial impact of this bacterium in a variety of preclinical models. Translating these exciting observations to human would be the next logic step and it now appears that several obstacles that would prevent the use of administration in humans have been overcome. Moreover, several lines of evidence indicate that pasteurization of not only increases its stability but more importantly increases its efficacy. This strongly positions in the forefront of next-generation candidates for developing novel food or pharma supplements with beneficial effects. Finally, a specific protein present on the outer membrane of , termed Amuc_1100, could be strong candidate for future drug development. In conclusion, as plants and its related knowledge, known as pharmacognosy, have been the source for designing drugs over the last century, we propose that microbes and microbiomegnosy, or knowledge of our gut microbiome, can become a novel source of future therapies.
与肥胖和心脏代谢紊乱相关的代谢紊乱在全球范围内流行。在不同的环境因素中，肠道微生物群现在被认为是干扰能量代谢和宿主对几种非传染性疾病易感性的关键因素。在已确定的下一代有益微生物中，是一个有前途的候选者。事实上，与肥胖、糖尿病、心脏代谢疾病和低度炎症呈负相关。除了观察到的众多相关性外，大量证据表明这种细菌在各种临床前模型中具有因果有益影响。将这些令人兴奋的观察结果转化到人类身上将是下一步合乎逻辑的步骤，现在看来，一些可能阻碍在人类中使用给药的障碍已经被克服。此外，几条证据表明，巴氏杀菌不仅提高了它的稳定性，更重要的是提高了它的功效。这使它在开发具有有益效果的新型食品或药物补充剂的下一代候选者中处于前沿地位。最后，存在于外膜上的一种特定蛋白质，称为Amuc_1100，可能是未来药物开发的有力候选者。总之，由于植物及其相关知识，即生药学，在上个世纪一直是设计药物的来源，我们提出微生物和微生物组学，即我们肠道微生物组的知识，可以成为未来治疗的新来源。
